WordPress database error: [The table 'wp_options' is full]
UPDATE `wp_options` SET `option_value` = 'a:15:{s:21:\"id_slug_type_path_map\";a:1:{i:1431;a:3:{s:4:\"slug\";s:16:\"ilab-media-tools\";s:4:\"type\";s:6:\"plugin\";s:4:\"path\";s:37:\"ilab-media-tools/ilab-media-tools.php\";}}s:11:\"plugin_data\";a:1:{s:16:\"ilab-media-tools\";a:30:{s:16:\"plugin_main_file\";O:8:\"stdClass\":1:{s:4:\"path\";s:37:\"ilab-media-tools/ilab-media-tools.php\";}s:20:\"is_network_activated\";b:0;s:17:\"install_timestamp\";i:1590575783;s:17:\"was_plugin_loaded\";b:1;s:21:\"is_plugin_new_install\";b:0;s:16:\"sdk_last_version\";s:5:\"2.6.2\";s:11:\"sdk_version\";s:5:\"2.7.0\";s:16:\"sdk_upgrade_mode\";b:1;s:18:\"sdk_downgrade_mode\";b:0;s:19:\"plugin_last_version\";s:5:\"4.6.2\";s:14:\"plugin_version\";s:5:\"4.6.4\";s:19:\"plugin_upgrade_mode\";b:1;s:21:\"plugin_downgrade_mode\";b:0;s:17:\"connectivity_test\";a:6:{s:12:\"is_connected\";b:1;s:4:\"host\";s:16:\"virusreports.net\";s:9:\"server_ip\";s:12:\"91.187.95.36\";s:9:\"is_active\";b:1;s:9:\"timestamp\";i:1590575783;s:7:\"version\";s:6:\"3.3.21\";}s:15:\"prev_is_premium\";b:0;s:12:\"is_anonymous\";a:3:{s:2:\"is\";b:1;s:9:\"timestamp\";i:1590575802;s:7:\"version\";s:6:\"3.3.21\";}s:14:\"has_trial_plan\";b:0;s:22:\"install_sync_timestamp\";i:1669820589;s:19:\"keepalive_timestamp\";i:1669820589;s:16:\"last_license_key\";s:32:\"29a39c221b0aa00cce0f4662daf6542b\";s:20:\"last_license_user_id\";N;s:15:\"is_whitelabeled\";b:0;s:20:\"activation_timestamp\";i:1590576202;s:13:\"subscriptions\";a:1:{i:0;O:15:\"FS_Subscription\":20:{s:2:\"id\";s:6:\"104441\";s:7:\"updated\";s:19:\"2020-05-27 11:18:22\";s:7:\"created\";s:19:\"2020-05-27 10:43:19\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:7:\"user_id\";s:7:\"3108640\";s:10:\"install_id\";s:7:\"4721959\";s:7:\"plan_id\";s:4:\"4634\";s:10:\"license_id\";s:6:\"360855\";s:11:\"total_gross\";d:8.99;s:16:\"amount_per_cycle\";d:8.99;s:13:\"billing_cycle\";i:1;s:19:\"outstanding_balance\";i:0;s:15:\"failed_payments\";i:0;s:7:\"gateway\";s:6:\"paypal\";s:11:\"external_id\";s:14:\"I-GS60RRYM35BC\";s:10:\"trial_ends\";N;s:12:\"next_payment\";N;s:11:\"canceled_at\";s:19:\"2020-05-27 11:18:22\";s:6:\"vat_id\";N;s:12:\"country_code\";s:2:\"ad\";}}s:9:\"beta_data\";a:2:{s:7:\"is_beta\";b:0;s:7:\"version\";s:6:\"3.3.23\";}s:14:\"sync_timestamp\";i:1669820589;s:9:\"sync_cron\";O:8:\"stdClass\":5:{s:7:\"version\";s:6:\"3.3.21\";s:7:\"blog_id\";i:0;s:11:\"sdk_version\";s:5:\"2.3.1\";s:9:\"timestamp\";i:1590580984;s:2:\"on\";b:1;}s:21:\"trial_promotion_shown\";i:1593702258;s:30:\"affiliate_program_notice_shown\";i:1593702258;s:19:\"last_load_timestamp\";i:1788643010;}}s:13:\"file_slug_map\";a:2:{s:37:\"ilab-media-tools/ilab-media-tools.php\";s:16:\"ilab-media-tools\";s:45:\"ilab-media-tools-premium/ilab-media-tools.php\";s:16:\"ilab-media-tools\";}s:7:\"plugins\";a:1:{s:16:\"ilab-media-tools\";O:9:\"FS_Plugin\":24:{s:2:\"id\";s:4:\"1431\";s:7:\"updated\";N;s:7:\"created\";N;s:22:\"\0FS_Entity\0_is_updated\";b:1;s:10:\"public_key\";s:32:\"pk_f20e8088bc078daafd3a20b6f653d\";s:10:\"secret_key\";N;s:16:\"parent_plugin_id\";N;s:5:\"title\";s:11:\"Media Cloud\";s:4:\"slug\";s:16:\"ilab-media-tools\";s:12:\"premium_slug\";s:24:\"ilab-media-tools-premium\";s:4:\"type\";s:6:\"plugin\";s:20:\"affiliate_moderation\";s:8:\"selected\";s:19:\"is_wp_org_compliant\";b:1;s:22:\"premium_releases_count\";N;s:4:\"file\";s:37:\"ilab-media-tools/ilab-media-tools.php\";s:7:\"version\";s:5:\"4.6.4\";s:11:\"auto_update\";N;s:4:\"info\";N;s:10:\"is_premium\";b:0;s:14:\"premium_suffix\";s:9:\"(Premium)\";s:7:\"is_live\";b:1;s:9:\"bundle_id\";N;s:17:\"bundle_public_key\";N;s:17:\"opt_in_moderation\";N;}}s:9:\"unique_id\";s:32:\"76bc5468b0fafc3e561fa1535364edb6\";s:5:\"plans\";a:1:{s:16:\"ilab-media-tools\";a:7:{i:0;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"MjA1NQ==\";s:7:\"updated\";s:28:\"MjAxOS0wMS0yMCAxNTowNjo0Mg==\";s:7:\"created\";s:28:\"MjAxNy0wOS0zMCAwOTozOToxNg==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:8:\"ZnJlZQ==\";s:5:\"title\";s:8:\"RnJlZQ==\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";N;s:13:\"support_forum\";N;s:13:\"support_email\";N;s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:1;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NDYzMg==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNDowMg==\";s:7:\"created\";s:28:\"MjAxOC0xMi0wOSAxNzowNTozMw==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:8:\"YmFzaWM=\";s:5:\"title\";s:8:\"QmFzaWM=\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:0:\"\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:4:\"MQ==\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"aGVscEBtZWRpYWNsb3VkLnByZXNz\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:2;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NzA2MA==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNDo0Ng==\";s:7:\"created\";s:28:\"MjAxOS0wOC0xNiAxODoyNzowMQ==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:20:\"bXVsdGlzaXRlX2Jhc2lj\";s:5:\"title\";s:20:\"TXVsdGlzaXRlIEJhc2lj\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3Mv\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"aGVscEBtZWRpYWNsb3VkLnByZXNz\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:3;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NDYzNA==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyMzoyMA==\";s:7:\"created\";s:28:\"MjAxOC0xMi0wOSAxNzowOToxOA==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:4:\"cHJv\";s:5:\"title\";s:4:\"UHJv\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:0:\"\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:4:\"MQ==\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"aGVscEBtZWRpYWNsb3VkLnByZXNz\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:4:\"MQ==\";s:9:\"is_hidden\";N;}i:4;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NzIxNg==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNToxNQ==\";s:7:\"created\";s:28:\"MjAxOS0wOC0yOSAwNDo0NDoxMA==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:20:\"bXVsdGlzaXRlX3Bybw==\";s:5:\"title\";s:20:\"TXVsdGlzaXRlIFBybw==\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"am9uQGludGVyZmFjZWxhYi5jb20=\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:5;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NzIxNw==\";s:7:\"updated\";s:28:\"MjAyMC0wNy0xNSAxNzoyNTozOA==\";s:7:\"created\";s:28:\"MjAxOS0wOC0yOSAwNDo1MDoxOQ==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:28:\"bXVsdGlzaXRlX3VubGltaXRlZA==\";s:5:\"title\";s:28:\"TXVsdGlzaXRlIFVubGltaXRlZA==\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:4:\"MQ==\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:0:\"\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"am9uQGludGVyZmFjZWxhYi5jb20=\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:0:\"\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}i:6;O:14:\"FS_Plugin_Plan\":22:{s:2:\"id\";s:8:\"NDYzNQ==\";s:7:\"updated\";s:28:\"MjAyMC0wOS0wNCAxNzoyNToxNg==\";s:7:\"created\";s:28:\"MjAxOC0xMi0wOSAxNzoxODoyMw==\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:8:\"MTQzMQ==\";s:4:\"name\";s:8:\"YWdlbmN5\";s:5:\"title\";s:8:\"QWdlbmN5\";s:11:\"description\";N;s:17:\"is_free_localhost\";s:4:\"MQ==\";s:17:\"is_block_features\";s:0:\"\";s:12:\"license_type\";s:4:\"MA==\";s:16:\"is_https_support\";s:0:\"\";s:12:\"trial_period\";N;s:23:\"is_require_subscription\";s:4:\"MQ==\";s:10:\"support_kb\";s:44:\"aHR0cHM6Ly9zdXBwb3J0Lm1lZGlhY2xvdWQucHJlc3M=\";s:13:\"support_forum\";N;s:13:\"support_email\";s:28:\"am9uQGludGVyZmFjZWxhYi5jb20=\";s:13:\"support_phone\";N;s:13:\"support_skype\";N;s:18:\"is_success_manager\";s:4:\"MQ==\";s:11:\"is_featured\";s:0:\"\";s:9:\"is_hidden\";N;}}}s:14:\"active_plugins\";O:8:\"stdClass\":3:{s:9:\"timestamp\";i:1615474488;s:3:\"md5\";s:32:\"1e32a299fdcdafa009ca51c5cb9bc76c\";s:7:\"plugins\";a:23:{s:19:\"akismet/akismet.php\";a:5:{s:4:\"slug\";s:7:\"akismet\";s:7:\"version\";s:5:\"4.1.5\";s:5:\"title\";s:17:\"Akismet Anti-Spam\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:11:\"amp/amp.php\";a:5:{s:4:\"slug\";s:3:\"amp\";s:7:\"version\";s:5:\"1.5.3\";s:5:\"title\";s:3:\"AMP\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:63:\"www-xml-sitemap-generator-org/www-xml-sitemap-generator-org.php\";a:5:{s:4:\"slug\";s:29:\"www-xml-sitemap-generator-org\";s:7:\"version\";s:5:\"1.3.4\";s:5:\"title\";s:28:\"Google XML Sitemap Generator\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:65:\"newsomatic-news-post-generator/newsomatic-news-post-generator.php\";a:5:{s:4:\"slug\";s:30:\"newsomatic-news-post-generator\";s:7:\"version\";s:5:\"2.4.4\";s:5:\"title\";s:35:\"Newsomatic Automatic Post Generator\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:57:\"ssl-insecure-content-fixer/ssl-insecure-content-fixer.php\";a:5:{s:4:\"slug\";s:26:\"ssl-insecure-content-fixer\";s:7:\"version\";s:5:\"2.7.2\";s:5:\"title\";s:26:\"SSL Insecure Content Fixer\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"td-cloud-library/td-cloud-library.php\";a:5:{s:4:\"slug\";s:16:\"td-cloud-library\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Cloud Library\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:27:\"td-composer/td-composer.php\";a:5:{s:4:\"slug\";s:11:\"td-composer\";s:7:\"version\";s:31:\"2.6 | built on 06.05.2020 14:38\";s:5:\"title\";s:15:\"tagDiv Composer\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"td-mobile-plugin/td-mobile-plugin.php\";a:5:{s:4:\"slug\";s:16:\"td-mobile-plugin\";s:7:\"version\";s:31:\"1.4 | built on 06.05.2020 14:38\";s:5:\"title\";s:19:\"tagDiv Mobile Theme\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:31:\"td-newsletter/td-newsletter.php\";a:5:{s:4:\"slug\";s:13:\"td-newsletter\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:17:\"tagDiv Newsletter\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:39:\"td-social-counter/td-social-counter.php\";a:5:{s:4:\"slug\";s:17:\"td-social-counter\";s:7:\"version\";s:31:\"4.7 | built on 06.05.2020 14:38\";s:5:\"title\";s:21:\"tagDiv Social Counter\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"td-standard-pack/td-standard-pack.php\";a:5:{s:4:\"slug\";s:16:\"td-standard-pack\";s:7:\"version\";s:36:\"1.0 BETA | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Standard Pack\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:81:\"update-theme-and-plugins-from-zip-file/update-theme-and-plugins-from-zip-file.php\";a:5:{s:4:\"slug\";s:38:\"update-theme-and-plugins-from-zip-file\";s:7:\"version\";s:5:\"1.1.1\";s:5:\"title\";s:38:\"Update Theme and Plugins from Zip File\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:31:\"wp-statistics/wp-statistics.php\";a:5:{s:4:\"slug\";s:13:\"wp-statistics\";s:7:\"version\";s:7:\"12.6.13\";s:5:\"title\";s:13:\"WP Statistics\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:37:\"ilab-media-tools/ilab-media-tools.php\";a:15:{s:4:\"Name\";s:11:\"Media Cloud\";s:9:\"PluginURI\";s:48:\"https://github.com/interfacelab/ilab-media-tools\";s:7:\"Version\";s:6:\"3.3.21\";s:11:\"Description\";s:150:\"Automatically upload media to Amazon S3 and integrate with Imgix, a real-time image processing CDN. Boosts site performance and simplifies workflows.\";s:6:\"Author\";s:12:\"interfacelab\";s:9:\"AuthorURI\";s:22:\"http://interfacelab.io\";s:10:\"TextDomain\";s:16:\"ilab-media-tools\";s:10:\"DomainPath\";s:0:\"\";s:7:\"Network\";b:0;s:10:\"RequiresWP\";s:0:\"\";s:11:\"RequiresPHP\";s:0:\"\";s:5:\"Title\";s:11:\"Media Cloud\";s:10:\"AuthorName\";s:12:\"interfacelab\";s:9:\"is_active\";b:1;s:4:\"slug\";s:16:\"ilab-media-tools\";}s:29:\"a3-lazy-load/a3-lazy-load.php\";a:5:{s:4:\"slug\";s:12:\"a3-lazy-load\";s:7:\"version\";s:5:\"2.3.2\";s:5:\"title\";s:12:\"a3 Lazy Load\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:49:\"autoremove-attachments/autoremove-attachments.php\";a:5:{s:4:\"slug\";s:22:\"autoremove-attachments\";s:7:\"version\";s:5:\"1.1.2\";s:5:\"title\";s:22:\"Autoremove Attachments\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:43:\"remove-category-url/remove-category-url.php\";a:5:{s:4:\"slug\";s:19:\"remove-category-url\";s:7:\"version\";s:5:\"1.1.6\";s:5:\"title\";s:19:\"Remove Category URL\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:74:\"wp-404-auto-redirect-to-similar-post/wp-404-auto-redirect-similar-post.php\";a:5:{s:4:\"slug\";s:36:\"wp-404-auto-redirect-to-similar-post\";s:7:\"version\";s:5:\"1.0.3\";s:5:\"title\";s:36:\"WP 404 Auto Redirect to Similar Post\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:27:\"wp-super-cache/wp-cache.php\";a:5:{s:4:\"slug\";s:14:\"wp-super-cache\";s:7:\"version\";s:5:\"1.7.1\";s:5:\"title\";s:14:\"WP Super Cache\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:31:\"ninjafirewall/ninjafirewall.php\";a:5:{s:4:\"slug\";s:13:\"ninjafirewall\";s:7:\"version\";s:5:\"4.2.5\";s:5:\"title\";s:26:\"NinjaFirewall (WP Edition)\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:55:\"remove-yoast-seo-comments/remove-yoast-seo-comments.php\";a:5:{s:4:\"slug\";s:25:\"remove-yoast-seo-comments\";s:7:\"version\";s:3:\"3.1\";s:5:\"title\";s:25:\"Remove Yoast SEO Comments\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:39:\"simple-wp-sitemap/simple-wp-sitemap.php\";a:5:{s:4:\"slug\";s:17:\"simple-wp-sitemap\";s:7:\"version\";s:5:\"1.2.1\";s:5:\"title\";s:17:\"Simple Wp Sitemap\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}s:24:\"wordpress-seo/wp-seo.php\";a:5:{s:4:\"slug\";s:13:\"wordpress-seo\";s:7:\"version\";s:4:\"15.0\";s:5:\"title\";s:9:\"Yoast SEO\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}}}s:11:\"all_plugins\";O:8:\"stdClass\":3:{s:9:\"timestamp\";i:1610722496;s:3:\"md5\";s:32:\"1ff5e8068ccc517ab9df7827a605c79e\";s:7:\"plugins\";a:24:{s:19:\"akismet/akismet.php\";a:6:{s:4:\"slug\";s:7:\"akismet\";s:7:\"version\";s:5:\"4.1.5\";s:5:\"title\";s:17:\"Akismet Anti-Spam\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"4.1.8\";}s:11:\"amp/amp.php\";a:6:{s:4:\"slug\";s:3:\"amp\";s:7:\"version\";s:5:\"1.5.3\";s:5:\"title\";s:3:\"AMP\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"2.0.10\";}s:63:\"www-xml-sitemap-generator-org/www-xml-sitemap-generator-org.php\";a:6:{s:4:\"slug\";s:29:\"www-xml-sitemap-generator-org\";s:7:\"version\";s:5:\"1.3.4\";s:5:\"title\";s:28:\"Google XML Sitemap Generator\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"1.3.5\";}s:37:\"ilab-media-tools/ilab-media-tools.php\";a:6:{s:4:\"slug\";s:16:\"ilab-media-tools\";s:7:\"version\";s:6:\"3.3.21\";s:5:\"title\";s:11:\"Media Cloud\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"4.1.14\";}s:65:\"newsomatic-news-post-generator/newsomatic-news-post-generator.php\";a:6:{s:4:\"slug\";s:30:\"newsomatic-news-post-generator\";s:7:\"version\";s:5:\"2.4.4\";s:5:\"title\";s:35:\"Newsomatic Automatic Post Generator\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:7:\"3.0.1.3\";}s:57:\"ssl-insecure-content-fixer/ssl-insecure-content-fixer.php\";a:5:{s:4:\"slug\";s:26:\"ssl-insecure-content-fixer\";s:7:\"version\";s:5:\"2.7.2\";s:5:\"title\";s:26:\"SSL Insecure Content Fixer\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:37:\"td-cloud-library/td-cloud-library.php\";a:6:{s:4:\"slug\";s:16:\"td-cloud-library\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Cloud Library\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:30:\"1.5 | built on 17.06.2020 8:12\";}s:27:\"td-composer/td-composer.php\";a:6:{s:4:\"slug\";s:11:\"td-composer\";s:7:\"version\";s:31:\"2.6 | built on 06.05.2020 14:38\";s:5:\"title\";s:15:\"tagDiv Composer\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:30:\"2.6 | built on 17.06.2020 8:12\";}s:37:\"td-mobile-plugin/td-mobile-plugin.php\";a:6:{s:4:\"slug\";s:16:\"td-mobile-plugin\";s:7:\"version\";s:31:\"1.4 | built on 06.05.2020 14:38\";s:5:\"title\";s:19:\"tagDiv Mobile Theme\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:30:\"1.4 | built on 17.06.2020 8:12\";}s:31:\"td-newsletter/td-newsletter.php\";a:5:{s:4:\"slug\";s:13:\"td-newsletter\";s:7:\"version\";s:31:\"1.5 | built on 06.05.2020 14:38\";s:5:\"title\";s:17:\"tagDiv Newsletter\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:39:\"td-social-counter/td-social-counter.php\";a:5:{s:4:\"slug\";s:17:\"td-social-counter\";s:7:\"version\";s:31:\"4.7 | built on 06.05.2020 14:38\";s:5:\"title\";s:21:\"tagDiv Social Counter\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:37:\"td-standard-pack/td-standard-pack.php\";a:5:{s:4:\"slug\";s:16:\"td-standard-pack\";s:7:\"version\";s:36:\"1.0 BETA | built on 06.05.2020 14:38\";s:5:\"title\";s:20:\"tagDiv Standard Pack\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:81:\"update-theme-and-plugins-from-zip-file/update-theme-and-plugins-from-zip-file.php\";a:6:{s:4:\"slug\";s:38:\"update-theme-and-plugins-from-zip-file\";s:7:\"version\";s:5:\"1.1.1\";s:5:\"title\";s:38:\"Update Theme and Plugins from Zip File\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"2.0.0\";}s:31:\"wp-statistics/wp-statistics.php\";a:6:{s:4:\"slug\";s:13:\"wp-statistics\";s:7:\"version\";s:7:\"12.6.13\";s:5:\"title\";s:13:\"WP Statistics\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"13.0.5\";}s:49:\"wp-statistics-rest-api/wp-statistics-rest-api.php\";a:5:{s:4:\"slug\";s:22:\"wp-statistics-rest-api\";s:7:\"version\";s:5:\"1.2.2\";s:5:\"title\";s:24:\"WP Statistics - REST API\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:29:\"a3-lazy-load/a3-lazy-load.php\";a:6:{s:4:\"slug\";s:12:\"a3-lazy-load\";s:7:\"version\";s:5:\"2.3.2\";s:5:\"title\";s:12:\"a3 Lazy Load\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"2.4.3\";}s:49:\"autoremove-attachments/autoremove-attachments.php\";a:6:{s:4:\"slug\";s:22:\"autoremove-attachments\";s:7:\"version\";s:5:\"1.1.2\";s:5:\"title\";s:22:\"Autoremove Attachments\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"1.2.1\";}s:43:\"remove-category-url/remove-category-url.php\";a:5:{s:4:\"slug\";s:19:\"remove-category-url\";s:7:\"version\";s:5:\"1.1.6\";s:5:\"title\";s:19:\"Remove Category URL\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:74:\"wp-404-auto-redirect-to-similar-post/wp-404-auto-redirect-similar-post.php\";a:5:{s:4:\"slug\";s:36:\"wp-404-auto-redirect-to-similar-post\";s:7:\"version\";s:5:\"1.0.3\";s:5:\"title\";s:36:\"WP 404 Auto Redirect to Similar Post\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:27:\"wp-super-cache/wp-cache.php\";a:5:{s:4:\"slug\";s:14:\"wp-super-cache\";s:7:\"version\";s:5:\"1.7.1\";s:5:\"title\";s:14:\"WP Super Cache\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:31:\"ninjafirewall/ninjafirewall.php\";a:6:{s:4:\"slug\";s:13:\"ninjafirewall\";s:7:\"version\";s:5:\"4.2.5\";s:5:\"title\";s:26:\"NinjaFirewall (WP Edition)\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:5:\"4.3.1\";}s:55:\"remove-yoast-seo-comments/remove-yoast-seo-comments.php\";a:5:{s:4:\"slug\";s:25:\"remove-yoast-seo-comments\";s:7:\"version\";s:3:\"3.1\";s:5:\"title\";s:25:\"Remove Yoast SEO Comments\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:39:\"simple-wp-sitemap/simple-wp-sitemap.php\";a:5:{s:4:\"slug\";s:17:\"simple-wp-sitemap\";s:7:\"version\";s:5:\"1.2.1\";s:5:\"title\";s:17:\"Simple Wp Sitemap\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;}s:24:\"wordpress-seo/wp-seo.php\";a:6:{s:4:\"slug\";s:13:\"wordpress-seo\";s:7:\"version\";s:4:\"15.0\";s:5:\"title\";s:9:\"Yoast SEO\";s:9:\"is_active\";b:0;s:14:\"is_uninstalled\";b:0;s:7:\"Version\";s:6:\"15.6.2\";}}}s:10:\"all_themes\";O:8:\"stdClass\":3:{s:9:\"timestamp\";i:1615474488;s:3:\"md5\";s:32:\"c7608adb62521fe1c683d1fdd1039cf9\";s:6:\"themes\";a:1:{s:9:\"Newspaper\";a:5:{s:4:\"slug\";s:9:\"Newspaper\";s:7:\"version\";s:6:\"10.3.5\";s:5:\"title\";s:9:\"Newspaper\";s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;}}}s:5:\"sites\";a:1:{s:16:\"ilab-media-tools\";O:7:\"FS_Site\":26:{s:2:\"id\";s:7:\"4721959\";s:7:\"updated\";s:19:\"2022-11-11 15:49:12\";s:7:\"created\";s:19:\"2020-05-27 10:43:17\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:10:\"public_key\";s:32:\"pk_6e950b674c6966af990cfa14cff7d\";s:10:\"secret_key\";s:32:\"sk_J}Yv][+DKV$b?j1Qoh3aj*?5FO78K\";s:7:\"site_id\";s:8:\"29644807\";s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:5:\"title\";s:12:\"Virus Report\";s:3:\"url\";s:24:\"https://virusreports.net\";s:7:\"version\";s:6:\"4.5.11\";s:8:\"language\";s:5:\"en-US\";s:16:\"platform_version\";s:5:\"5.8.6\";s:11:\"sdk_version\";s:5:\"2.4.5\";s:28:\"programming_language_version\";s:6:\"7.4.30\";s:7:\"plan_id\";s:4:\"2055\";s:10:\"license_id\";N;s:13:\"trial_plan_id\";N;s:10:\"trial_ends\";N;s:10:\"is_premium\";b:0;s:15:\"is_disconnected\";b:0;s:9:\"is_active\";b:1;s:14:\"is_uninstalled\";b:0;s:7:\"is_beta\";b:0;s:7:\"charset\";s:5:\"UTF-8\";}}s:5:\"users\";a:1:{i:3108640;O:7:\"FS_User\":13:{s:2:\"id\";s:7:\"3108640\";s:7:\"updated\";s:19:\"2020-05-27 10:43:19\";s:7:\"created\";s:19:\"2020-05-27 10:43:16\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:10:\"public_key\";s:32:\"pk_d59257bb9e82a4b8e004a8c305a03\";s:10:\"secret_key\";s:32:\"sk_[~lJoxs51=yv_[!0boAFtR!qH^N88\";s:5:\"email\";s:16:\"vizboo@yahoo.com\";s:5:\"first\";s:6:\"vizboo\";s:4:\"last\";s:2:\"yu\";s:11:\"is_verified\";b:0;s:11:\"customer_id\";N;s:5:\"gross\";i:0;s:7:\"is_beta\";b:0;}}s:23:\"user_id_license_ids_map\";a:1:{i:1431;a:1:{i:3108640;a:3:{i:0;i:360876;i:1;i:360858;i:2;i:360855;}}}s:12:\"all_licenses\";a:1:{i:1431;a:3:{i:0;O:17:\"FS_Plugin_License\":21:{s:2:\"id\";s:6:\"360876\";s:7:\"updated\";s:19:\"2020-06-08 11:08:49\";s:7:\"created\";s:19:\"2020-05-27 11:00:50\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:7:\"plan_id\";s:4:\"4634\";s:16:\"parent_plan_name\";N;s:17:\"parent_plan_title\";N;s:17:\"parent_license_id\";N;s:8:\"products\";N;s:10:\"pricing_id\";s:4:\"3792\";s:5:\"quota\";i:1;s:9:\"activated\";i:1;s:15:\"activated_local\";i:0;s:10:\"expiration\";s:19:\"2020-06-08 10:08:49\";s:10:\"secret_key\";s:32:\"sk_3sFp^Ov>pTgwHb!j6jnt0}=96-Ss;\";s:15:\"is_whitelabeled\";b:0;s:17:\"is_free_localhost\";b:1;s:17:\"is_block_features\";b:1;s:12:\"is_cancelled\";b:1;}i:1;O:17:\"FS_Plugin_License\":21:{s:2:\"id\";s:6:\"360858\";s:7:\"updated\";s:19:\"2020-05-27 11:00:50\";s:7:\"created\";s:19:\"2020-05-27 10:48:38\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:7:\"plan_id\";s:4:\"4634\";s:16:\"parent_plan_name\";N;s:17:\"parent_plan_title\";N;s:17:\"parent_license_id\";N;s:8:\"products\";N;s:10:\"pricing_id\";s:4:\"3792\";s:5:\"quota\";i:1;s:9:\"activated\";i:0;s:15:\"activated_local\";i:0;s:10:\"expiration\";s:19:\"2020-06-27 10:00:00\";s:10:\"secret_key\";s:32:\"sk_OH_+BJ<*Hk<QjK{L*oIu{quIxpo4y\";s:15:\"is_whitelabeled\";b:0;s:17:\"is_free_localhost\";b:1;s:17:\"is_block_features\";b:1;s:12:\"is_cancelled\";b:0;}i:2;O:17:\"FS_Plugin_License\":21:{s:2:\"id\";s:6:\"360855\";s:7:\"updated\";s:19:\"2020-06-27 14:55:34\";s:7:\"created\";s:19:\"2020-05-27 10:43:19\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:9:\"plugin_id\";s:4:\"1431\";s:7:\"user_id\";s:7:\"3108640\";s:7:\"plan_id\";s:4:\"4634\";s:16:\"parent_plan_name\";N;s:17:\"parent_plan_title\";N;s:17:\"parent_license_id\";N;s:8:\"products\";N;s:10:\"pricing_id\";s:4:\"3792\";s:5:\"quota\";i:1;s:9:\"activated\";i:0;s:15:\"activated_local\";i:0;s:10:\"expiration\";s:19:\"2020-06-27 10:00:00\";s:10:\"secret_key\";s:32:\"sk_I&Cicy<vyjUtE#Rd~cYWo}+;D4p_K\";s:15:\"is_whitelabeled\";b:0;s:17:\"is_free_localhost\";b:1;s:17:\"is_block_features\";b:1;s:12:\"is_cancelled\";b:0;}}}s:13:\"admin_notices\";a:1:{s:16:\"ilab-media-tools\";a:0:{}}s:7:\"updates\";a:1:{i:1431;O:13:\"FS_Plugin_Tag\":12:{s:2:\"id\";s:5:\"18751\";s:7:\"updated\";i:1593183304;s:7:\"created\";s:19:\"2020-06-26 05:18:34\";s:22:\"\0FS_Entity\0_is_updated\";b:0;s:7:\"version\";s:6:\"3.3.23\";s:3:\"url\";s:386:\"https://api.freemius.com/v1/installs/4721959/updates/18751.zip?is_premium=true&authorization=FSLA+4721959%3AiW00UNsMipIXufak3QeXd9sbagAr1QsjAJcrKDsZey3uBFSQt9BEh_ZkaMGt2e6XQSWXKpnWXoqLXjeM9MylAnaZn9DEln6QAUUPSz1qBsxQuzSparj2YBjnKPusOgZmAiQxRtU0lAc2A18Q8SkFvIT6WbV8BmNaHr5J0pfTBiH5hFsH6f6w7JUgJwmByN2S5QKL9Zuud0YHV4VGPaDmoUd1en0Y3AU06ZqHGHZhRbhe-G7v24kMWJ8zR6zD_JAhPa4MNgJ44C_dShqm807rSg\";s:25:\"requires_platform_version\";s:3:\"4.4\";s:37:\"requires_programming_language_version\";N;s:20:\"tested_up_to_version\";s:3:\"5.4\";s:8:\"has_free\";b:1;s:11:\"has_premium\";b:1;s:12:\"release_mode\";s:8:\"released\";}}}' WHERE `option_name` = 'fs_accounts'

WordPress database error: [The table 'wp_options' is full]
DELETE FROM `wp_options` WHERE `option_name` = '_site_transient_wp_theme_files_patterns-1de0d11b1124cfe2057b1fd8f32658d3'

WordPress database error: [The table 'wp_options' is full]
DELETE FROM `wp_options` WHERE `option_name` = '_site_transient_timeout_wp_theme_files_patterns-1de0d11b1124cfe2057b1fd8f32658d3'

WordPress database error: [The table 'wp_options' is full]
INSERT INTO `wp_options` (`option_name`, `option_value`, `autoload`) VALUES ('_site_transient_timeout_wp_theme_files_patterns-1de0d11b1124cfe2057b1fd8f32658d3', '1788644810', 'off') ON DUPLICATE KEY UPDATE `option_name` = VALUES(`option_name`), `option_value` = VALUES(`option_value`), `autoload` = VALUES(`autoload`)

WordPress database error: [The table 'wp_options' is full]
INSERT INTO `wp_options` (`option_name`, `option_value`, `autoload`) VALUES ('_site_transient_wp_theme_files_patterns-1de0d11b1124cfe2057b1fd8f32658d3', 'a:2:{s:7:\"version\";s:6:\"10.3.5\";s:8:\"patterns\";a:0:{}}', 'off') ON DUPLICATE KEY UPDATE `option_name` = VALUES(`option_name`), `option_value` = VALUES(`option_value`), `autoload` = VALUES(`autoload`)

WordPress database error: [The table 'wp_options' is full]
DELETE FROM `wp_options` WHERE `option_name` = '_transient_tsk_attachment_count'

WordPress database error: [The table 'wp_options' is full]
DELETE FROM `wp_options` WHERE `option_name` = '_transient_timeout_tsk_attachment_count'

WordPress database error: [The table 'wp_options' is full]
INSERT INTO `wp_options` (`option_name`, `option_value`, `autoload`) VALUES ('_transient_timeout_tsk_attachment_count', '1788729410', 'off') ON DUPLICATE KEY UPDATE `option_name` = VALUES(`option_name`), `option_value` = VALUES(`option_value`), `autoload` = VALUES(`autoload`)

WordPress database error: [The table 'wp_options' is full]
INSERT INTO `wp_options` (`option_name`, `option_value`, `autoload`) VALUES ('_transient_tsk_attachment_count', '51', 'off') ON DUPLICATE KEY UPDATE `option_name` = VALUES(`option_name`), `option_value` = VALUES(`option_value`), `autoload` = VALUES(`autoload`)

WordPress database error: [The table 'wp_options' is full]
DELETE FROM `wp_options` WHERE `option_name` = '_transient_tsk_posts_count'

WordPress database error: [The table 'wp_options' is full]
DELETE FROM `wp_options` WHERE `option_name` = '_transient_timeout_tsk_posts_count'

WordPress database error: [The table 'wp_options' is full]
INSERT INTO `wp_options` (`option_name`, `option_value`, `autoload`) VALUES ('_transient_timeout_tsk_posts_count', '1788729410', 'off') ON DUPLICATE KEY UPDATE `option_name` = VALUES(`option_name`), `option_value` = VALUES(`option_value`), `autoload` = VALUES(`autoload`)

WordPress database error: [The table 'wp_options' is full]
INSERT INTO `wp_options` (`option_name`, `option_value`, `autoload`) VALUES ('_transient_tsk_posts_count', 'a:2:{s:11:\"total_posts\";i:101;s:9:\"old_posts\";i:101;}', 'off') ON DUPLICATE KEY UPDATE `option_name` = VALUES(`option_name`), `option_value` = VALUES(`option_value`), `autoload` = VALUES(`autoload`)

WordPress database error: [The table 'wp_options' is full]
UPDATE `wp_options` SET `option_value` = '1788643010.9826819896697998046875' WHERE `option_name` = '_transient_doing_cron'


Warning: Cannot modify header information - headers already sent by (output started at /var/www/clients/client0/web46/web/wp-includes/class-wpdb.php:1845) in /var/www/clients/client0/web46/web/wp-includes/feed-rss2.php on line 8
<div id="error"><p class="wpdberror"><strong>WordPress database error:</strong> [The table 'wp_yoast_indexable' is full]<br /><code>UPDATE `wp_yoast_indexable` SET `object_id` = '1268', `object_type` = 'term', `object_sub_type` = 'post_tag', `permalink` = 'http://virusreports.net/tag/breakthrough/', `blog_id` = '1', `primary_focus_keyword_score` = NULL, `is_robots_noindex` = NULL, `is_public` = NULL, `open_graph_image` = NULL, `open_graph_image_id` = NULL, `open_graph_image_source` = NULL, `open_graph_image_meta` = NULL, `twitter_image` = NULL, `twitter_image_id` = NULL, `twitter_image_source` = NULL, `canonical` = NULL, `primary_focus_keyword` = NULL, `title` = NULL, `description` = NULL, `readability_score` = NULL, `inclusive_language_score` = NULL, `breadcrumb_title` = 'breakthrough', `open_graph_title` = NULL, `open_graph_description` = NULL, `twitter_title` = NULL, `twitter_description` = NULL, `is_cornerstone` = '0', `is_robots_nofollow` = NULL, `is_robots_noarchive` = NULL, `is_robots_noimageindex` = NULL, `is_robots_nosnippet` = NULL, `object_published_at` = '2020-04-20 11:26:57', `object_last_modified` = '2020-09-14 19:21:24', `version` = '2', `permalink_hash` = '41:a1a213882b71d99f965ceaad52ff5f47', `updated_at` = '2026-09-05 21:16:51' WHERE `id` = '30532'</code></p></div><div id="error"><p class="wpdberror"><strong>WordPress database error:</strong> [The table 'wp_yoast_indexable_hierarchy' is full]<br /><code>DELETE FROM `wp_yoast_indexable_hierarchy` WHERE `indexable_id` = '30532'</code></p></div><div id="error"><p class="wpdberror"><strong>WordPress database error:</strong> [Duplicate entry '30532-0' for key 'PRIMARY']<br /><code>INSERT INTO `wp_yoast_indexable_hierarchy` (`indexable_id`, `ancestor_id`, `depth`, `blog_id`) VALUES ('30532', '0', '0', '1')</code></p></div>breakthrough Archives - Virus Reports

WordPress database error: [The table 'wp_yoast_indexable' is full]
UPDATE `wp_yoast_indexable` SET `object_id` = '1268', `object_type` = 'term', `object_sub_type` = 'post_tag', `permalink` = 'http://virusreports.net/tag/breakthrough/', `blog_id` = '1', `primary_focus_keyword_score` = NULL, `is_robots_noindex` = NULL, `is_public` = NULL, `open_graph_image` = NULL, `open_graph_image_id` = NULL, `open_graph_image_source` = NULL, `open_graph_image_meta` = NULL, `twitter_image` = NULL, `twitter_image_id` = NULL, `twitter_image_source` = NULL, `canonical` = NULL, `primary_focus_keyword` = NULL, `title` = NULL, `description` = NULL, `readability_score` = NULL, `inclusive_language_score` = NULL, `breadcrumb_title` = 'breakthrough', `open_graph_title` = NULL, `open_graph_description` = NULL, `twitter_title` = NULL, `twitter_description` = NULL, `is_cornerstone` = '0', `is_robots_nofollow` = NULL, `is_robots_noarchive` = NULL, `is_robots_noimageindex` = NULL, `is_robots_nosnippet` = NULL, `object_published_at` = '2020-04-20 11:26:57', `object_last_modified` = '2020-09-14 19:21:24', `version` = '2', `permalink_hash` = '41:a1a213882b71d99f965ceaad52ff5f47', `updated_at` = '2026-09-05 21:16:51' WHERE `id` = '30532'

http://virusreports.net/tag/breakthrough/ Mon, 14 Sep 2020 19:21:24 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.7

WordPress database error: [The table 'wp_yoast_indexable' is full]
UPDATE `wp_yoast_indexable` SET `object_id` = '1268', `object_type` = 'term', `object_sub_type` = 'post_tag', `permalink` = 'http://virusreports.net/tag/breakthrough/', `blog_id` = '1', `primary_focus_keyword_score` = NULL, `is_robots_noindex` = NULL, `is_public` = NULL, `open_graph_image` = NULL, `open_graph_image_id` = NULL, `open_graph_image_source` = NULL, `open_graph_image_meta` = NULL, `twitter_image` = NULL, `twitter_image_id` = NULL, `twitter_image_source` = NULL, `canonical` = NULL, `primary_focus_keyword` = NULL, `title` = NULL, `description` = NULL, `readability_score` = NULL, `inclusive_language_score` = NULL, `breadcrumb_title` = 'breakthrough', `open_graph_title` = NULL, `open_graph_description` = NULL, `twitter_title` = NULL, `twitter_description` = NULL, `is_cornerstone` = '0', `is_robots_nofollow` = NULL, `is_robots_noarchive` = NULL, `is_robots_noimageindex` = NULL, `is_robots_nosnippet` = NULL, `object_published_at` = '2020-04-20 11:26:57', `object_last_modified` = '2020-09-14 19:21:24', `version` = '2', `permalink_hash` = '41:a1a213882b71d99f965ceaad52ff5f47', `updated_at` = '2026-09-05 21:16:51' WHERE `id` = '30532'

https://s3.us-west-1.wasabisys.com/virusreports/2020/05/cropped-virus-favicon-32x32.png breakthrough Archives - Virus Reports http://virusreports.net/tag/breakthrough/ 32 32 Massive breakthrough: 155 mm howitzer artillery destroys incoming cruise missile http://virusreports.net/massive-breakthrough-155-mm-howitzer-artillery-destroys-incoming-cruise-missile/ http://virusreports.net/massive-breakthrough-155-mm-howitzer-artillery-destroys-incoming-cruise-missile/#respond Mon, 14 Sep 2020 19:21:24 +0000 https://virusreports.net/massive-breakthrough-155-mm-howitzer-artillery-destroys-incoming-cruise-missile/ In an amazing first, an artillery cannon took out a cruise missile.An M109 Paladin 155 mm howitzer made history recently by shooting down a fast-moving maneuvering cruise missile with a “hypervelocity projectile” able to travel at speeds up to Mach 5, according to an Air Force announcement. Historically, armored vehicles such as tanks, howitzers or…

The post Massive breakthrough: 155 mm howitzer artillery destroys incoming cruise missile appeared first on Virus Reports.

]]>

In an amazing first, an artillery cannon took out a cruise missile.

An M109 Paladin 155 mm howitzer made history recently by shooting down a fast-moving maneuvering cruise missile with a “hypervelocity projectile” able to travel at speeds up to Mach 5, according to an Air Force announcement. Historically, armored vehicles such as tanks, howitzers or infantry carriers have not operated with an ability to destroy fast-moving, long-range cruise missiles, yet the successful demonstration breaks new ground.

The shoot-down, which took place at White Sands Missile Range, New Mexico, destroyed a “surrogate” Russian cruise missile target using the Air Force’s Advanced Battle Management System (ABMS).

CHINA WILL DOUBLE ITS ARSENAL OF NUCLEAR WARHEADS, REPORT SAYS

In development for several years now, ABMS represents an Air Force technical initiative to engineer a “meshed” network of otherwise disconnected sensor “nodes” throughout a theater of combat operations. While an Air Force program, the effort is intended by all estimations to inform the Pentagon’s broader Joint All Domain Command and Control (JADC2) technological system.

Artillerymen of 1st Battalion, 41st Field Artillery Regiment fire M109 Alpha 6 Paladins, on Tapa Army Base, Estonia, Nov. 27, 2015.

Artillerymen of 1st Battalion, 41st Field Artillery Regiment fire M109 Alpha 6 Paladins, on Tapa Army Base, Estonia, Nov. 27, 2015.
(U.S. Army photo by Sgt Caitlyn Byrne, 10th Press Camp Headquarters)

The concept with JADC2 is to integrate sensor-to-shooter capabilities across air-land-sea-space and cyber domains in real-time, decreasing latency, expediting attacks and bringing new dimensions to “joint warfare.”

“Future battlefields will be characterized by information saturation. One of the key objectives of this onramp was to present a dizzying array of information for participants to synthesize, just like they would see in a real operation,” Dr. Will Roper, assistant secretary of the Air Force for acquisition, technology and logistics, said in an Air Force report.

PENTAGON: CHINESE AIR FORCE FAST-BECOMING MASSIVE THREAT

Firing a hypervelocity projectile (HVP) from an artillery cannon is a concept that has been under development for many years, dating back to Roper’s time directing the Pentagon’s Strategic Capabilities Office. The origins of the HVP can be traced to the Navy’s Rail Gun developmental effort as well as initiatives intended to explore firing the HVP from deck-mounted guns on Navy surface ships.

Due to its ability to reach speeds of up to 5,600 miles per hour, the hypervelocity projectile is engineered as a kinetic energy warhead, meaning no explosives are necessary. It can travel at speeds up to 2,000 meters (6,562 feet) per second, a speed which is about three times that of most existing weapons. The weapon brings such force, power and range that could hold enemies at risk from greater distances and attack targets with the kinetic energy force equivalent to a multi-ton vehicle moving at 160 miles per hour, developers have said.

The success of the shoot-down, Roper added, relied upon the integration of artificial intelligence (AI)-enabled data analytics increasingly able to gather, organize and analyze data with great reliability in a near-instantaneous fashion. So not only will air-sea-and land targeting sensors have an ability to exchange information across otherwise disparate information systems, but AI-enabled algorithms can gather the data, perform near real-time analytics and efficiently distribute organized information where needed.

Longer-range sensors also further enable this technical possibility, allowing for bombers in the air, surface ships, fighter jets, drones and land-based command and control to operate across previously inaccessible vast distances.

NAVY ELECTRONIC WARFARE STOPS MULTIPLE ENEMY MISSILE ATTACKS AT ONCE

“This compelled commanders and operators to trust data analytics and artificial intelligence to understand the battle. Valuing data as an essential warfighting resource, one no less vital than jet fuel or satellites, is the key to next-gen warfare,” Roper said.

Cloud computing, Roper added, is among a series of AI-integrated technologies now ready for combat.

CLICK HERE TO GET THE FOX NEWS APP

AI-empowered algorithms can gather information and bounce new data off of a nearly limitless database to establish comparisons, identify items of relevance, perform analyses, solve problems and efficiently organize problem-solving “data.” The success of this relies upon a number of variables, including increased reliability of algorithms programmed to identify patterns, recognize essential indicators and provide the necessary context.

Kris Osborn is the Managing Editor of Warrior Maven and The Defense Editor of The National Interest.

Read More

The post Massive breakthrough: 155 mm howitzer artillery destroys incoming cruise missile appeared first on Virus Reports.

]]>
http://virusreports.net/massive-breakthrough-155-mm-howitzer-artillery-destroys-incoming-cruise-missile/feed/ 0
‘Breakthrough’ treatment slashes coronavirus death risk: UK study http://virusreports.net/breakthrough-treatment-slashes-coronavirus-death-risk-uk-study/ http://virusreports.net/breakthrough-treatment-slashes-coronavirus-death-risk-uk-study/#respond Mon, 20 Jul 2020 13:21:05 +0000 https://virusreports.net/breakthrough-treatment-slashes-coronavirus-death-risk-uk-study/ There are currently a number of treatments available for patients hospitalised with COVID-19 [File: Tolga Akmen/AFP] An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm. In a randomised trial of 100 patients admitted…

The post ‘Breakthrough’ treatment slashes coronavirus death risk: UK study appeared first on Virus Reports.

]]>

There are currently a number of treatments available for patients hospitalised with COVID-19 [File: Tolga Akmen/AFP]

There are currently a number of treatments available for patients hospitalised with COVID-19 [File: Tolga Akmen/AFP]

An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm.

In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the protein interferon beta were at 79 percent lower risk of developing the severe disease compared with those who received a placebo.

They were also more than twice as likely to make a full recovery compared with the control group.

The firm behind the treatment, known as SNG001, said the preliminary results suggested “a major breakthrough” in the pandemic.

“We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from requiring oxygen to requiring ventilation,” said Richard Marsden, CEO of Synairgen.

The results published on Monday have not yet been peer-reviewed and the sample size is relatively small. But if confirmed the treatment could revolutionise the way COVID-19 is dealt with in hospitals.

Interferon beta

Interferon beta is a naturally occurring protein, commonly used to treat multiple sclerosis.

It forms part of the body’s natural fight against infection, and the novel coronavirus suppresses its production in an attempt to evade an immune response.

Delivering the protein directly into the lungs of patients is designed to trigger a robust immune response to the virus, even in patients whose immune system is already weakened by infection.

“The results confirm our belief that interferon beta … has huge potential as an inhaled drug to be able to restore the lung’s immune response,” said Tom Wilkinson, professor of respiratory medicine at the University of Southampton.

He said the trial showed SNG001 was effective in “enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus”.

There are currently a number of treatments available for patients hospitalised with COVID-19.

Last month, a UK-based team of researchers led by the University of Oxford announced they had successfully reduced the risk of death among seriously ill patients by administering the commonly available steroid dexamethasone.

Several countries have also issued the emergency authorisation for treatment with anti-viral remdesivir.

SOURCE:
News agencies

Read More

The post ‘Breakthrough’ treatment slashes coronavirus death risk: UK study appeared first on Virus Reports.

]]>
http://virusreports.net/breakthrough-treatment-slashes-coronavirus-death-risk-uk-study/feed/ 0
Breakthrough Drug for Covid-19 May Be Risky for Mild Cases http://virusreports.net/breakthrough-drug-for-covid-19-may-be-risky-for-mild-cases/ http://virusreports.net/breakthrough-drug-for-covid-19-may-be-risky-for-mild-cases/#respond Thu, 25 Jun 2020 03:21:02 +0000 https://virusreports.net/breakthrough-drug-for-covid-19-may-be-risky-for-mild-cases/ That study about dexamethasone has arrived with a big asterisk: While it appears to help severely ill patients, it harms others.The steroid dexamethasone is cheap and easily obtained, but experts warned that people with mild illness — or no illness — should not take it. Credit...Andy Rain/EPA, via ShutterstockJune 24, 2020, 7:26 p.m. ETScientists in Britain…

The post Breakthrough Drug for Covid-19 May Be Risky for Mild Cases appeared first on Virus Reports.

]]>

That study about dexamethasone has arrived with a big asterisk: While it appears to help severely ill patients, it harms others.

Credit…Andy Rain/EPA, via Shutterstock

Roni Caryn Rabin

Scientists in Britain announced a major breakthrough in the battle against the coronavirus last week, reporting they had found the first drug to reduce deaths among critically ill Covid-19 patients.

The results were first made public in a sparsely detailed news release. Now the full study, neither peer reviewed nor published yet, has been posted online, and it holds a surprise.

The drug — a cheap, widely available steroid called dexamethasone — does seem to help patients in dire straits, the data suggest. But it also may be risky for patients with milder illness, and the timing of the treatment is critical.

The drug “may harm some patients, and we’re not entirely sure which patients those are,” said Dr. Samuel Brown, an assistant professor of pulmonary and critical care medicine at University of Utah School of Medicine in Salt Lake City, who was not involved in the research.

Following the announcement last week, officials at some American hospitals said that they would begin to treat coronavirus patients with dexamethasone, and the World Health Organization called for accelerating production to ensure an adequate supply. U.K. health officials moved to limit exports of the steroid.

The drug was tested in a clinical trial that included some 6,425 patients in Britain. One-third were randomly assigned to receive the drug, while the others received the usual care. Patients in the first group received a very low dose of the drug, given daily for up to 10 days.

Dexamethasone was beneficial for those who had been sick for more than a week, reducing deaths by one-third among patients on mechanical ventilators and by one-fifth among patients receiving supplemental oxygen by other means.

Patients given the steroid who were not receiving respiratory support, however, actually died at a slightly higher rate than similar patients who were not given the drug, although the difference was not statistically significant.

That the drug might have disparate effects at different stages of the disease makes sense, given the biology of the illness, according to Dr. Martin J. Landray, the study’s senior author and a professor of medicine and epidemiology at Oxford University.

In the most severely ill patients, the immune system flies into a harmful overdrive mode, triggering a so-called cytokine storm that damages the body, including the lungs.

“It’s almost like a disease with two phases,” Dr. Landray said in an interview. “A phase where the virus dominates, and the immunological phase, where the damage the immune system causes is dominant.”

Doctors have worried about using steroids such as dexamethasone to fight Covid-19, because steroids are anti-inflammatory drugs that dampen the body’s protective immune response. In mildly ill patients, that may do more harm than good, Dr. Landray said.

“In the early phase of the illness, the immune system is your friend,” Dr. Landray said. “It’s fighting the virus, and dampening it is not a good idea.”

  • Updated June 24, 2020

    • Is it harder to exercise while wearing a mask?

      A commentary published this month on the website of the British Journal of Sports Medicine points out that covering your face during exercise “comes with issues of potential breathing restriction and discomfort” and requires “balancing benefits versus possible adverse events.” Masks do alter exercise, says Cedric X. Bryant, the president and chief science officer of the American Council on Exercise, a nonprofit organization that funds exercise research and certifies fitness professionals. “In my personal experience,” he says, “heart rates are higher at the same relative intensity when you wear a mask.” Some people also could experience lightheadedness during familiar workouts while masked, says Len Kravitz, a professor of exercise science at the University of New Mexico.

    • I’ve heard about a treatment called dexamethasone. Does it work?

      The steroid, dexamethasone, is the first treatment shown to reduce mortality in severely ill patients, according to scientists in Britain. The drug appears to reduce inflammation caused by the immune system, protecting the tissues. In the study, dexamethasone reduced deaths of patients on ventilators by one-third, and deaths of patients on oxygen by one-fifth.

    • What is pandemic paid leave?

      The coronavirus emergency relief package gives many American workers paid leave if they need to take time off because of the virus. It gives qualified workers two weeks of paid sick leave if they are ill, quarantined or seeking diagnosis or preventive care for coronavirus, or if they are caring for sick family members. It gives 12 weeks of paid leave to people caring for children whose schools are closed or whose child care provider is unavailable because of the coronavirus. It is the first time the United States has had widespread federally mandated paid leave, and includes people who don’t typically get such benefits, like part-time and gig economy workers. But the measure excludes at least half of private-sector workers, including those at the country’s largest employers, and gives small employers significant leeway to deny leave.

    • Does asymptomatic transmission of Covid-19 happen?

      So far, the evidence seems to show it does. A widely cited paper published in April suggests that people are most infectious about two days before the onset of coronavirus symptoms and estimated that 44 percent of new infections were a result of transmission from people who were not yet showing symptoms. Recently, a top expert at the World Health Organization stated that transmission of the coronavirus by people who did not have symptoms was “very rare,” but she later walked back that statement.

    • What’s the risk of catching coronavirus from a surface?

      Touching contaminated objects and then infecting ourselves with the germs is not typically how the virus spreads. But it can happen. A number of studies of flu, rhinovirus, coronavirus and other microbes have shown that respiratory illnesses, including the new coronavirus, can spread by touching contaminated surfaces, particularly in places like day care centers, offices and hospitals. But a long chain of events has to happen for the disease to spread that way. The best way to protect yourself from coronavirus — whether it’s surface transmission or close human contact — is still social distancing, washing your hands, not touching your face and wearing masks.

    • How does blood type influence coronavirus?

      A study by European scientists is the first to document a strong statistical link between genetic variations and Covid-19, the illness caused by the coronavirus. Having Type A blood was linked to a 50 percent increase in the likelihood that a patient would need to get oxygen or to go on a ventilator, according to the new study.

    • How many people have lost their jobs due to coronavirus in the U.S.?

      The unemployment rate fell to 13.3 percent in May, the Labor Department said on June 5, an unexpected improvement in the nation’s job market as hiring rebounded faster than economists expected. Economists had forecast the unemployment rate to increase to as much as 20 percent, after it hit 14.7 percent in April, which was the highest since the government began keeping official statistics after World War II. But the unemployment rate dipped instead, with employers adding 2.5 million jobs, after more than 20 million jobs were lost in April.

    • What are the symptoms of coronavirus?

      Common symptoms include fever, a dry cough, fatigue and difficulty breathing or shortness of breath. Some of these symptoms overlap with those of the flu, making detection difficult, but runny noses and stuffy sinuses are less common. The C.D.C. has also added chills, muscle pain, sore throat, headache and a new loss of the sense of taste or smell as symptoms to look out for. Most people fall ill five to seven days after exposure, but symptoms may appear in as few as two days or as many as 14 days.

    • How can I protect myself while flying?

      If air travel is unavoidable, there are some steps you can take to protect yourself. Most important: Wash your hands often, and stop touching your face. If possible, choose a window seat. A study from Emory University found that during flu season, the safest place to sit on a plane is by a window, as people sitting in window seats had less contact with potentially sick people. Disinfect hard surfaces. When you get to your seat and your hands are clean, use disinfecting wipes to clean the hard surfaces at your seat like the head and arm rest, the seatbelt buckle, the remote, screen, seat back pocket and the tray table. If the seat is hard and nonporous or leather or pleather, you can wipe that down, too. (Using wipes on upholstered seats could lead to a wet seat and spreading of germs rather than killing them.)

    • What should I do if I feel sick?

      If you’ve been exposed to the coronavirus or think you have, and have a fever or symptoms like a cough or difficulty breathing, call a doctor. They should give you advice on whether you should be tested, how to get tested, and how to seek medical treatment without potentially infecting or exposing others.


[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]

“In the later phase, the immune system is no longer your friend — it’s responsible for the lungs failing, and dampening it down with steroids helps the situation and improves the chance of survival.”

Other experts agreed, saying the study showed dexamethasone cannot be used to treat mild illness, or as a preventive.

“It would likely be harmful to take dexamethasone as an outpatient treatment for Covid-19,” said Dr. Brown. Patients with mild infections “should not be trying to get people to prescribe them dexamethasone just in case.”

Many scientists want to see the trial results repeated in another study, and note that some questions aren’t fully answered in the paper, including information about long-term outcomes and neurological damage.

“If a reasonable fraction of patients are recovering in a way that’s satisfactory and welcome, what you have is a gigantic victory,” said Dr. Jeremy Faust, an emergency room physician at Brigham and Women’s Hospital in Boston.

Generally, however, patients who have spent a long time on ventilators “have a rough road ahead,” he added, even if dexamethasone improves their odds of survival.

Read More

The post Breakthrough Drug for Covid-19 May Be Risky for Mild Cases appeared first on Virus Reports.

]]>
http://virusreports.net/breakthrough-drug-for-covid-19-may-be-risky-for-mild-cases/feed/ 0
In possible breakthrough, Israeli lab claims successful vaccine trial on rodents http://virusreports.net/in-possible-breakthrough-israeli-lab-claims-successful-vaccine-trial-on-rodents/ http://virusreports.net/in-possible-breakthrough-israeli-lab-claims-successful-vaccine-trial-on-rodents/#respond Sun, 21 Jun 2020 09:21:01 +0000 https://virusreports.net/in-possible-breakthrough-israeli-lab-claims-successful-vaccine-trial-on-rodents/ In a possible breakthrough, an Israeli Defense Ministry-run laboratory claimed it had completed successful coronavirus vaccine trials on rodents, paving the way to further testing on other animals and then possibly human trials. In a paper published Friday on the website of bioRxiv, an online repository for papers that haven’t yet been peer-reviewed, the Israel…

The post In possible breakthrough, Israeli lab claims successful vaccine trial on rodents appeared first on Virus Reports.

]]>

In a possible breakthrough, an Israeli Defense Ministry-run laboratory claimed it had completed successful coronavirus vaccine trials on rodents, paving the way to further testing on other animals and then possibly human trials.

In a paper published Friday on the website of bioRxiv, an online repository for papers that haven’t yet been peer-reviewed, the Israel Institute for Biological Research, which is based in Ness Ziona, said it hopes to have a finished vaccine in a year, or possibly even earlier.

In the abstract of the report, the researchers say their vaccine, which they tested on hamsters, “results in rapid and potent induction of neutralizing antibodies against SARS-CoV-2,” the virus that causes COVID-19.


Get The Times of Israel’s Daily Edition by email and never miss our top stories


Free Sign Up

During the trials, two groups of rodents were infected with the coronavirus, but only one group had first been given the vaccine. Whereas the unvaccinated group became sick, the vaccinated rodents remained healthy, researchers claimed.

“Importantly, single-dose vaccination was able to protect hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss of the immunized hamsters compared to unvaccinated hamsters,” they wrote in the report.

While the lungs of infected hamsters showed extensive tissue damage and a high viral load, the report said that those given the vaccine “showed only minor lung pathology” and had no viral titer.

Testing on rodents is a key preliminary stage in developing medicines and enables further testing to begin on other animals. If those are also successful, the trials will move to humans to check the vaccine’s effectiveness and for any side effects, the report said.

The Israel Institute for Biological Research, is seen in this file photo, hidden behind shrubs and barbed-wire in the Israeli town of Ness Tziona, south of Tel Aviv, Oct. 14,1998. (AP Photo/Mark Levie)

Earlier this month, the laboratory confirmed that it had isolated an antibody it believed could be used to develop treatments for COVID-19, and that it was ahead of the world in those efforts. This would not be useful in the creation of a vaccine, but would rather be a move toward a drug treatment for those who have already contracted the disease.

While a number of scientific institutions around the world have discovered antibodies capable of destroying the COVID-19 virus, the laboratory said at the time it was the first in the world to reach three major milestones: finding an antibody that destroys the virus; that targets this coronavirus specifically; and that is monoclonal, lacking additional proteins that can cause complications for patients.

The secretive research institute was thrust into the headlines after outgoing defense minister Naftali Bennett announced the isolation of the antibody in March, though the announcement appeared to have been premature.

According to a report by Israel’s Channel 12 news last week, the laboratory has since identified eight antibodies to COVID-19 and filed for an international patent on the technology. The antibodies were produced from blood taken from COVID-19 patients who developed serious symptoms, and then recovered. The lab hopes to combine the antibodies into an effective treatment for the virus. If researchers are able to make the medicine, they will seek an international drug company to mass produce it.

About 100 research groups around the world are pursuing vaccines for the coronavirus, with nearly a dozen in early stages of human trials or poised to start. But so far there is no way to predict which — if any — vaccine will work safely, or even to name a front-runner.

Dr. Anthony Fauci, the US government’s top expert, has cautioned that even if everything goes perfectly, developing a vaccine in 12 to 18 months would set a record for speed.

The coronavirus has infected over 4.7 million people and killed more than 315,000 worldwide, according to the Worldometer website that experts say under-counts the true toll of the pandemic. Israel has had over 20,000 diagnosed cases of COVID-19, with 305 deaths as of Sunday.

Read More

The post In possible breakthrough, Israeli lab claims successful vaccine trial on rodents appeared first on Virus Reports.

]]>
http://virusreports.net/in-possible-breakthrough-israeli-lab-claims-successful-vaccine-trial-on-rodents/feed/ 0
‘Breakthrough’ coronavirus treatment dexamethasone is a ‘good first step,’ lead researcher says http://virusreports.net/breakthrough-coronavirus-treatment-dexamethasone-is-a-good-first-step-lead-researcher-says/ http://virusreports.net/breakthrough-coronavirus-treatment-dexamethasone-is-a-good-first-step-lead-researcher-says/#respond Wed, 17 Jun 2020 01:21:00 +0000 https://virusreports.net/breakthrough-coronavirus-treatment-dexamethasone-is-a-good-first-step-lead-researcher-says/ The new potential coronavirus treatment dexamethasone is a "good first step" to finding a cocktail of drugs that can effectively treat Covid-19, Oxford University professor Martin Landray, who co-led the study that found the drug to improve survival among patients, told CNBC on Tuesday.Landray and his team earlier Tuesday published the results of a study, which has…

The post ‘Breakthrough’ coronavirus treatment dexamethasone is a ‘good first step,’ lead researcher says appeared first on Virus Reports.

]]>

The new potential coronavirus treatment dexamethasone is a “good first step” to finding a cocktail of drugs that can effectively treat Covid-19, Oxford University professor Martin Landray, who co-led the study that found the drug to improve survival among patients, told CNBC on Tuesday.

Landray and his team earlier Tuesday published the results of a study, which has not been peer-reviewed, that show the cheap steroid cut the risk of death by a third for Covid-19 patients on ventilators, and by a fifth for those on supplemental oxygen. The underlying data from the study has yet to be published, but the U.K. researchers who led the trial described the results as “a major breakthrough.”

The drug is the first to show signs that it can improve survival among Covid-19 patients, the researchers said. There are currently no drugs approved by the FDA for the treatment of the disease caused by the coronavirus, which has killed at least 438,843 people around the world.

Landray told CNBC that the drug appears to effectively combat some aspects of the disease, but a treatment regimen in combination with other therapeutics, like an antiviral drug or antibody treatment, could prove to be even more effective in preventing death.

“It’s very likely that we’ll end up with a situation where a combination of drugs are used, just as we see in HIV, just as we see in heart disease, in many other areas of medicine,” he said on CNBC’s “Closing Bell.” “But this is the first step. It’s a good first step.”

Dexamethasone, a steroid medication that’s been used for decades to treat conditions like arthritis and asthma, is cheap and widely available, Landray said. He added that the drug combats Covid-19 by “dampening” the body’s immune response, which in the sickest patients “almost turns against the body.” This phenomenon, referred to by doctors as a cytokine storm, can severely damage Covid-19 patients’ lungs and result in death.

In order to build on the study’s findings, researchers will hopefully find a drug or therapeutic that attacks the virus itself rather than the body’s response to the disease, Landray said. Such a drug could potentially be taken in conjunction with dexamethasone to create a robust combination treatment.

“It’s a cheap drug, widely available — that’s going to be first line therapy,” he said. “And the question is do these other drugs now work on top of dexamethasone.”

Gilead’s remdesivir would be one such antiviral drug, but it has not proven to improve a patient’s chances of surviving Covid-19. Studies have indicated remdesivir shortens the recovery time for patients.

While dexamethasone effectively treated hospitalized patients enrolled in Landray’s study, it did not have a beneficial effect on patients who were not sick enough to require respiratory support. Most people infected with the virus will not require hospitalization or respiratory support, according to data from the Centers for Disease Control and Prevention.

“This is not a treatment for the community,” Landray said. “This is a treatment for the sickest patients. But if you had to have a drug and choose where it was going to work, you’d choose for it to work in the very high-risk group, the sickest patients.”

While more research is needed and the study still needs to be reviewed, Landray said that “thousands of patients are dying each day” and the findings from his study are “good for patients today.”

Read More

The post ‘Breakthrough’ coronavirus treatment dexamethasone is a ‘good first step,’ lead researcher says appeared first on Virus Reports.

]]>
http://virusreports.net/breakthrough-coronavirus-treatment-dexamethasone-is-a-good-first-step-lead-researcher-says/feed/ 0
Coronavirus breakthrough as patients stop being infectious after two weeks http://virusreports.net/coronavirus-breakthrough-as-patients-stop-being-infectious-after-two-weeks/ http://virusreports.net/coronavirus-breakthrough-as-patients-stop-being-infectious-after-two-weeks/#respond Mon, 25 May 2020 05:21:44 +0000 https://virusreports.net/coronavirus-breakthrough-as-patients-stop-being-infectious-after-two-weeks/ The findings come from scientists from Singapore's National Centre for Infectious Diseases and the Academy of Medicine. The research finds that person infected with COVID-19 becomes contagious around two days before symptoms show. The study then holds that the patients then remain contagious for between seven and ten days after they start showing signs of…

The post Coronavirus breakthrough as patients stop being infectious after two weeks appeared first on Virus Reports.

]]>

The findings come from scientists from Singapore’s National Centre for Infectious Diseases and the Academy of Medicine.

The research finds that person infected with COVID-19 becomes contagious around two days before symptoms show.

The study then holds that the patients then remain contagious for between seven and ten days after they start showing signs of the disease.

This includes having a high temperature and a new and continuous cough.

Researchers said COVID-19 “could not be isolated or cultured after day 11 of the illness.

READ MORE: Coronavirus conspiracy? Covid-19 was ‘adapted to infect humans’ shock claim

singapore

CORONAVIRUS patients stop being infectious after 11 days, according to a study from Singapore. (Image: PA)

patient

The findings come from scientists from Singapore’s National Center for Infectious Diseases and the Academy of Medicine. (Image: PA)

Positive tests in patients that still had symptoms after two weeks could be picking up sections of the bug that cannot pass the virus on to someone else.

The study examined 73 patients infected with COVID-19.

The authors wrote: “Based on the accumulated data since the start of the COVID-19 pandemic, the infectious period of [coronavirus] in symptomatic individuals may begin around two days before the onset of symptoms, and persists for about seven to ten days after the onset of symptoms.

“Active viral replication drops quickly after the first week, and viable virus was not found after the second week of illness.”

patients

Researchers said COVID-19 “could not be isolated or cultured after day 11” of the illness. (Image: PA)

NCID executive director Leo Yee Sin said: “Scientifically, I’m very confident that there is enough evidence that the person is no longer infectious after 11 days.”

Dr Asok Kurup, who chairs the chapter in the academy, is equally confident about the results.

The infectious diseases expert in private practice said: “Studies are still going on and we will get more data, but we will see the same thing as there is a great deal of science in this.

“So there is no need to wait.”

DON’T MISS:

Mortgage payment holidays extended to October [UPDATES]


When do Sainsbury’s, Tesco, Morrisons, Lidl, and Aldi open? [INSIGHT]

Coronavirus map LIVE: Vaccine boost as drug induces immune response [REVEALED]

The UK death toll has hit more than 36,000

The UK death toll has hit more than 36,000 (Image: EXPRESS)

Recently, 18 patients who had mild symptoms were released after spending between 38 and 51 days in a care facility, despite continuing to test positive.

Singapore’s Ministry Of Health said they were shedding “dead viral components”, which, though detectable in testing, were inactive.

They had to quarantine themselves for seven days after their release.

When asked about the new study, the MOH said it “will closely study the position statement and evaluate how we can incorporate the latest evidence… into our patient clinical management plan”.

patient

The research confirms a previous study in Germany, that similarly holds that COVID-19 patients stop shedding the virus by day 8 of infection. (Image: PA)

The research confirms a previous study in Germany, that similarly holds that COVID-19 patients stop shedding the virus by day 8 of infection.

When asked why it took three days longer in Singapore, Prof Leo said the researchers here were “very conservative and counted till the very last drop”.

The only exceptions to this are patients with weakened immune systems, such as cancer patients receiving chemotherapy or people on immunosuppressant drugs following a transplant.

The virus in them might remain viable for a longer period.

Read More

The post Coronavirus breakthrough as patients stop being infectious after two weeks appeared first on Virus Reports.

]]>
http://virusreports.net/coronavirus-breakthrough-as-patients-stop-being-infectious-after-two-weeks/feed/ 0
Possible breakthrough in coronavirus-related syndrome in children http://virusreports.net/possible-breakthrough-in-coronavirus-related-syndrome-in-children/ http://virusreports.net/possible-breakthrough-in-coronavirus-related-syndrome-in-children/#respond Sun, 17 May 2020 19:21:49 +0000 https://virusreports.net/possible-breakthrough-in-coronavirus-related-syndrome-in-children/ Doctors have identified a group of blood compounds that may help to reveal which children are most at risk of developing a rare but life-threatening immune reaction to coronavirus. The new syndrome emerged last month after hospitals in London admitted a number of children to intensive care units with symptoms that resembled toxic shock mixed…

The post Possible breakthrough in coronavirus-related syndrome in children appeared first on Virus Reports.

]]>

Doctors have identified a group of blood compounds that may help to reveal which children are most at risk of developing a rare but life-threatening immune reaction to coronavirus.

The new syndrome emerged last month after hospitals in London admitted a number of children to intensive care units with symptoms that resembled toxic shock mixed with an inflammatory disorder known as Kawasaki disease.

The World Health Organization (WHO) guidance on face masks has remained consistent during the coronavirus pandemic. It has stuck to the line that masks are for healthcare workers – not the public. 

“Wearing a medical mask is one of the prevention measures that can limit the spread of certain respiratory viral diseases, including Covid-19. However, the use of a mask alone is insufficient to provide an adequate level of protection, and other measures should also be adopted,” the WHO has stated.

Nevertheless, as some countries have eased lockdown conditions, they have been making it mandatory to wear face coverings outside, as a way of trying to inhibit spread of the virus. This is in the belief that the face covering will prevent people who cough and sneeze ejecting the virus any great distance. 

There is no robust scientific evidence – in the form of trials – that ordinary masks block the virus from infecting people who wear them. There is also concerns the public will not understand how to use a mask properly, and may get infected if they come into contact with the virus when they take it off and then touch their faces.

Also underlying the WHO’s concerns is the shortage of high-quality protective masks for frontline healthcare workers.

Nevertheless, masks do have a role when used by people who are already infected. It is accepted that they can block transmission to other people. Given that many people with Covid-19 do not show any symptoms for the first days after they are infected, masks clearly have a potential role to play, especially on crowded public transport as people return to work..

 Sarah Boseley Health editor

Hospitals around the world have since reported hundreds of similar cases that many doctors believe are caused by the immune system overreacting to the virus sometimes weeks after infection.

About 100 children in Britain have been treated for the disease. Many have been admitted with a persistent fever, skin rashes, abdominal pain and cold hands or feet. At least two children in the UK have died of the disorder, one of whom was an eight-month-old baby at Plymouth’s Derriford hospital in April.

Researchers at Imperial College London analysed blood from some of the sickest children and found they had high levels of five compounds that can be measured in routine tests. Two of the compounds, ferritin and C-reactive protein or CRP, are common blood markers for inflammation. The others are linked to heart damage and blood clotting, namely troponin, BNP and so-called “D-dimers”.

“We know that these markers are present in the very sick patients and at lower levels in some patients with normal Kawasaki disease,” said Michael Levin, a professor of paediatrics and international child health at Imperial.

“We think they can help us decide which children are at risk of progressing to cardiac failure. Essentially what we’re doing is using the blood markers to try and pick out the children that we need to move from district hospitals to specialist centres and then to intensive care units if needed.”

It will take more research to work out if the markers are reliable. If they are, doctors could potentially identify children most at risk from the condition with a simple blood test.

To investigate further, the researchers have been granted permission from England’s chief medical officer, Prof Chris Whitty, to recruit children into a European-funded trial called Diamonds that was already underway to study inflammatory disorders. Doctors around the UK and in various hospitals in Europe are now collecting blood samples for the study to learn which markers may help them predict the severity of disease and to understand the genetics of the disorder.

“This is a rapidly changing situation and we desperately need to learn how to manage it because we are now seeing quite significant numbers of children being admitted to district hospitals all over the place,” Levin said.

“What we don’t know when we’re seeing a child for the first time, or hearing about them if they’re at another hospital, is which children are going to get better on their own and which are going to progress to having Kawasaki disease and are therefore at risk of getting coronary artery aneurysms, and who are the small number who will progress to multi-organ failure.”

The condition, named paediatric inflammatory multisystem syndrome, resembles a mix of toxic shock and Kawasaki disease, the latter of which overwhelmingly affects children. The disease causes inflammation of the blood vessels and in some cases attacks the heart. The most serious complications are coronary aneurysms which can be fatal when they clot. Doctors typically intervene swiftly with anti-inflammatory drugs or immune-suppressing medicines.

Doctors do not have time to run a formal trial to learn which treatments work best. Instead, plans have been drawn up for an international database they will use to enter anonymous information on children in their care, including blood test results and what treatments are given when. “It’s not as good as a randomised trial, but it’s the next best thing in a pandemic. Because the numbers will be so big, it might give us a signal as to which treatments are best,” Levin said.

Prof Russell Viner, the president of the Royal College of Paediatrics and Child Health, said it was too early to know how beneficial blood biomarkers might be for stratifying children with the new inflammatory disease.

“This peak will tail off as the whole Covid peak tails off and we are already seeing that,” Viner said. “But if Covid is going to be with us for a while, and there’s going to be a rise in Covid cases, we are going to see more of these cases. So we absolutely need ways of identifying early on which children might have this as opposed to a child who just presents with a fever, so biomarkers might be exceptionally helpful in the longer term.”

Read More

The post Possible breakthrough in coronavirus-related syndrome in children appeared first on Virus Reports.

]]>
http://virusreports.net/possible-breakthrough-in-coronavirus-related-syndrome-in-children/feed/ 0
UofL breakthrough technology shows promise fighting novel coronavirus http://virusreports.net/uofl-breakthrough-technology-shows-promise-fighting-novel-coronavirus/ http://virusreports.net/uofl-breakthrough-technology-shows-promise-fighting-novel-coronavirus/#respond Wed, 22 Apr 2020 20:23:35 +0000 https://virusreports.net/uofl-breakthrough-technology-shows-promise-fighting-novel-coronavirus/ COVID-19. University of Louisville researchers have developed a technology that is believed to block the novel coronavirus SARS-CoV-2 from infecting human cells. The technology is based on a piece of synthetic DNA – an “aptamer” –  which targets and binds with a human protein called nucleolin. Early tests show that this aptamer may stop viruses,…

The post UofL breakthrough technology shows promise fighting novel coronavirus appeared first on Virus Reports.

]]>
COVID-19.
COVID-19.

University of Louisville researchers have developed a technology that is believed to block the novel coronavirus SARS-CoV-2 from infecting human cells.

The technology is based on a piece of synthetic DNA – an “aptamer” –  which targets and binds with a human protein called nucleolin. Early tests show that this aptamer may stop viruses, including novel coronavirus, from “hijacking” nucleolin to replicate inside the body.  

UofL is seeking to fast-track development, including application to the Food and Drug Administration for approval to start treating patients seriously affected with COVID-19.  

The aptamer was discovered by UofL’s Paula Bates, John Trent and Don Miller, who have applied it in a variety of ways, most notably as a potential therapeutic drug against multiple types of cancer. With the current global pandemic of coronavirus and the COVID-19 disease it causes, Bates partnered with fellow researcher Kenneth Palmer to apply the technology once again.

“Like many scientists, as soon as I heard about the new coronavirus, I wanted to help and started to think about how my area of research might intersect with coronavirus research efforts,” said Bates, a professor of medicine. “I am fortunate to be at UofL, which is one of the few places in the country where we have the facilities to do experiments using the SARS-CoV-2 virus.”

Palmer, director of UofL’s Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), conducted proof-of-concept experiments showing the aptamer was effective against the virus at doses previous research has shown to be safe in patients. Palmer also is working on another potential COVID-19 treatment, Q-Griffithsin, developed at UofL in partnership with the National Cancer Institute and the University of Pittsburgh. 

The CPM houses UofL’s Regional Biocontainment Laboratory, one of only 12 regional and two national biocontainment labs in the United States and the only one in Kentucky. Established with support from the NIH to conduct research with infectious agents, the lab includes Biosafety Level 3 facilities built to the most exacting federal safety and security standards. The stringently secure facilities protect researchers and the public from exposure to the pathogens being investigated. 

UofL is providing financial support for COVID-19 research, but additional funds are needed to continue the work over time. Donations specifically for the research can be made online here.

Read More

The post UofL breakthrough technology shows promise fighting novel coronavirus appeared first on Virus Reports.

]]>
http://virusreports.net/uofl-breakthrough-technology-shows-promise-fighting-novel-coronavirus/feed/ 0
Bipartisan breakthrough? Pols unveil ‘Back to Work’ plan for reopening economy with emphasis on mass testing http://virusreports.net/bipartisan-breakthrough-pols-unveil-back-to-work-plan-for-reopening-economy-with-emphasis-on-mass-testing/ http://virusreports.net/bipartisan-breakthrough-pols-unveil-back-to-work-plan-for-reopening-economy-with-emphasis-on-mass-testing/#respond Mon, 20 Apr 2020 11:26:57 +0000 https://virusreports.net/bipartisan-breakthrough-pols-unveil-back-to-work-plan-for-reopening-economy-with-emphasis-on-mass-testing/ EXCLUSIVE: After spending weeks diving into coronavirus issues over video conferencing, a bipartisan group of 50 House members has crafted a plan for what's needed to reopen the economy safely and help businesses recover from crippling mandatory shutdowns.Fox News got an exclusive first look at the Problem Solvers Caucus plan that outlines specific public health, economic recovery and long-term stimulus plans the…

The post Bipartisan breakthrough? Pols unveil ‘Back to Work’ plan for reopening economy with emphasis on mass testing appeared first on Virus Reports.

]]>

EXCLUSIVE: After spending weeks diving into coronavirus issues over video conferencing, a bipartisan group of 50 House members has crafted a plan for what’s needed to reopen the economy safely and help businesses recover from crippling mandatory shutdowns.

Fox News got an exclusive first look at the Problem Solvers Caucus plan that outlines specific public health, economic recovery and long-term stimulus plans the group wants Congress and President Trump to embrace as the nation tries to emerge from weekslong quarantines and growing mass layoffs.

“The bottom line is people I think are eager for a checklist. They want to understand what we think it takes to get everything moving again,” Rep. Josh Gottheimer, D-N.J., co-chair of the Problem Solvers Caucus, told Fox News.

READ THE PROBLEM SOLVERS CAUCUS PLAN HERE

The Problem Solvers Caucus on Monday will unveil publicly its “Back to Work” checklist that is poised to be an influential framework in Washington in future rounds of coronavirus relief packages. The plan got the green light from the group of pragmatic lawmakers determined to deliver Americans some relief.

“What this checklist does is it shows that if you’re sincere and you want to put partisan politics aside … you can actually roll up your sleeves and you can find some common ground that makes a lot of good common sense,” Rep. Tom Reed, R-N.Y., co-chair of the Problem Solvers Caucus, told Fox News. “It also shows that you can get the necessary votes at 218 and 60 to get it done [in the House and Senate.]”

TRUMP UNVEILS CORONAVIRUS GUIDELINES FOR ROLLING BACK SOCIAL DISTANCING IN PHASES: ‘NEXT FRONT IN OUR WAR’

The White House already released its plan for a three-phased gradual opening led by states, but it was panned by some governors and Speaker Nancy Pelosi as being too vague and not stressing mass rapid testing and contact tracing.

But at the top of the list for bipartisan lawmakers’ checklist is the importance of rapid mass COVID-19 testing — at a scale that could be upwards of five times greater than what’s currently happening. The Problem Solvers Caucus checklist calls for establishing a federal contact tracing database, similar to how the federal government already tracks measles.

The lawmakers say the supply chain for personal protective gear also needs to ramp up to cover workers in all essential sectors, from food service to schools. Their checklist calls for all K-12 children and teachers having access to protective masks to return to school.

“In the short run, we need to do it to get our schools back open,” Gottheimer said of having teachers and students wear masks. “That’s part of the precaution we’re going to have to take. If you’re in an area in New York and New Jersey that’s been hit hardest, we want to take every precaution.”

SPEAKER PELOSI RIPS TRUMP AS ‘WEAK LEADER,’ TELLS ‘FOX NEWS SUNDAY’ HE’S FAILED ON CORONAVIRUS RESPONSE

Operating under the principle that a vaccine likely won’t be available for at least another year, lawmakers say they needed to look at establishing a “new normal” in American society of regularly wearing protective gear as regions and states slowly get back to work. While acknowledging regional and economic differences, the plan sets national benchmarks that must be met to reopen the United States, which has been hard hit with at least 22 million new layoffs and more than 750,000 COVID-19 infections. The lawmakers recommend re-configuring business layouts for social distancing, ramping up cleaning and sanitizing public spaces and workplaces, and adopting data-driving benchmarks that will trigger the Department of Homeland Security to implement travel restrictions to and from infected countries.

In terms of economic recovery, the Problem Solvers Caucus says the U.S. needs to establish new supply chains for manufactured goods, including pharmaceuticals and medical supplies, and give financial incentives to bring overseas manufacturers back to the United States.

The plan calls for more business help, with expanding low-interest loans and tax incentives to businesses that were forced to close under stay-at-home orders. The lawmakers also want more federal aid to the agricultural sector to shore up food supplies.

And in a nod to calls from the progressive left, the Problem Solvers are calling for nationwide help for mortgage and rent payments. “We must find a way to afford relief, either through long-term loans, rental relief, forgiveness, or temporary forbearance for renters and homeowners, while, at the same time, ensuring liquidity of related lenders and landlords,” the checklist states to help stabilize the commercial, retail and homeownership markets.

The plan calls for real-time reporting mechanisms to share data on hospital capacity and supplies, coordinating regional and national health care workers for deployment to hot zones, shoring up supplies needed for a vaccine and therapeutic treatments and more federal money for the healthcare sector, states and local governments.

CLICK HERE FOR FULL CORONAVIRUS COVERAGE

Longer term, the 50 lawmakers say the federal government will need to pass a substantial stimulus plan to restart the economy that should include a “historic investment in our nation’s infrastructure.”

The 50 members are equally divided between Republicans and Democrats. Any proposal must win the support of 75 percent of the membership to be adopted and this plan comfortably cleared the hurdle, the leaders said, proving it can get passed in Congress.

“If we can get to 75 percent-plus consensus, that’s a pretty good indication that these are solid ideas substantively that can bring people together,” Reed said.

While dealing with the coronavirus response in their own districts, the Problem Solvers members continued to meet as a caucus through video meetings to draft the plan, consult with senators and speak with experts, including former Food and Drug Administration Commissioner Dr. Scott Gottlieb.

In the last four weeks, the Problem Solvers Caucus held seven full meetings, five working groups and four meetings with senators to complete the plan.

“What this proposal is doing is really trying to lay some groundwork. We need to do a better job of looking over the horizon and around the corners,” Reed said. “And I’ll tell you we’ve learned so much over the last four weeks.”

A main public health priority the bipartisan lawmakers have emphasized is rapid testing for diagnosing COVID-19 and also serological testing to see who has developed antibodies. They will require the FDA to continue to approve testing methods and for companies to ramp up production to hit the benchmark.

Reed and Gottheimer together set the goal at 750,000 tests per day in an earlier op-ed — although Monday’s plan doesn’t name a specific figure. Currently, the U.S. is testing on average about 150,000 people a day, according to data from the COVID Tracking Project, which means much more work needs to be done for the U.S. to safely meet the goals to reopen the economy.

“The overall point is that we need to have testing,” said Gottheimer, who is also a member of the new White House congressional task force on reopening the economy. “It’s critical to be able to fully reopen.”

MODERATE DEMS ACKNOWLEDGE COUNTRY DIVISION AT ‘ROCK BOTTOM’ FOLLOWING IMPEACHMENT, PLEDGE CONGRESS CAN STILL WORK

The proposal now heads to congressional leadership and Trump to help guide the process. Some of the requirements could need executive and agency action, while others need congressional support.  Their goal is to set out a framework for governing and give the American people a road map for the recovery

“We’re going through this crisis for the next two years — by the time you get to a vaccine and the economic recovery,” Reed said, in explaining the immediate, short-term and longer-term goals of the plan.

“There’s all different pieces to this at the state and federal, and local level that we’re hoping this has an impact on,” added Gottheimer. “And my hope is that this is used as a checklist for others … and as a way for people to feel comfortable that we actually are making important progress in this country [and] that we are moving toward getting back to work, which is absolutely essential as long as it’s done safely.”

Read More

The post Bipartisan breakthrough? Pols unveil ‘Back to Work’ plan for reopening economy with emphasis on mass testing appeared first on Virus Reports.

]]>
http://virusreports.net/bipartisan-breakthrough-pols-unveil-back-to-work-plan-for-reopening-economy-with-emphasis-on-mass-testing/feed/ 0